Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of AL vs DP for Uncomplicated Malaria in Guinea-Bissau
NCT01704508Phase 4Completed
- Sponsor
- Bandim Health Project
- Start
- Nov 2012
- Primary completion
- Oct 2015
- Modality
- Bivalent/Multivalent Binders, Nucleic Acid-Directed Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of dihydroartemisinin + piperaquine in Plasmodium falciparum malaria (2 arms), sponsored by Bandim Health Project. Primary endpoint: Adequate Clinical and Parasitological Response at 42 days. Started Nov 2012; status: completed.
02
Drugs
dihydroartemisinin + piperaquine
03
Conditions
Plasmodium falciparum malaria
Beyond the preview
Go deeper on NCT01704508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01704508.